ID   TU-3
AC   CVCL_QX95
DR   cancercelllines; CVCL_QX95
DR   Wikidata; Q54973323
RX   CelloPub=CLPUB00455;
RX   PubMed=9249875;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (PubMed=9249875).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 19-12-24; Version: 11
//
RX   CelloPub=CLPUB00455;
RA   Koskela K., Pelliniemi T.-T., Remes K., Savino R., Ciliberto G.,
RA   Pulkki K.;
RT   "Establishment of three new myeloma cell lines from bone marrow plasma
RT   cells: response to interleukin-6 and interleukin-6-antagonist.";
RL   (In conference) Proceedings of the Vth international workshop on multiple myeloma; pp.3.83-3.83; International Myeloma Foundation; La Baule; France (1995).
//
RX   PubMed=9249875; DOI=10.3109/00365519709099401;
RA   Ollikainen H., Syrjanen S.M., Koskela K., Pelliniemi T.-T., Pulkki K.;
RT   "p53 gene mutations are rare in patients but common in
RT   patient-originating cell lines in multiple myeloma.";
RL   Scand. J. Clin. Lab. Invest. 57:281-289(1997).
//